Rating Change
LUCID CAPITAL MARKETS analysts initiated coverage on Eloxx Pharmaceuticals, Inc. (OTC:ELOX) with a rating of Buy on August 20, 2026.
new coverageOTC:ELOX
LUCID CAPITAL MARKETS Initiates Coverage on Eloxx Pharmaceuticals, Inc. (ELOX) with Buy
LUCID CAPITAL MARKETS analysts initiated coverage on Eloxx Pharmaceuticals, Inc. (OTC:ELOX) with a rating of Buy on August 20, 2026.
At publication ·
What changed
Eloxx Pharmaceuticals, Inc. (OTC:ELOX) · new coverage
- Firm
- LUCID CAPITAL MARKETS
- Rating
- Buy
- Price at event
- $18.04
- Market capitalization
- $314.0
At a glance
Key takeaways
- LUCID CAPITAL MARKETS initiated Buy coverage on Eloxx Pharmaceuticals (ELOX) on August 20, 2026, with the stock trading at $18.04 and a market capitalization of $314.0 million.
- Among the 10 most recent analyst ratings, 7 are Buy, 3 are Hold, and 0 are Sell, indicating predominantly positive sentiment toward the company.
Market Context
Eloxx Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $18.04 with a market capitalization of 314.0.
Analyst coverage from LUCID CAPITAL MARKETS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eloxx Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Eloxx Pharmaceuticals, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | LUCID CAPITAL MARKETS | Buy | N/A |
| Jul 22, 2026 | LifeSci Capital | Outperform | N/A |
| Jul 20, 2026 | Guggenheim | Buy | N/A |
| Jul 11, 2023 | Oppenheimer | Outperform | N/A |
| Apr 06, 2023 | Oppenheimer | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ELOX Stock Page
Frequently Asked Questions
What does the Buy rating mean for ELOX?
A rating of Buy from LUCID CAPITAL MARKETS reflects the analyst's outlook on Eloxx Pharmaceuticals, Inc. (OTC:ELOX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ELOX forecast page.
